{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:50:27Z","timestamp":1777521027009,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12916-017-0875-8","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T15:33:07Z","timestamp":1496331187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":157,"title":["Number needed to treat (NNT) in clinical literature: an appraisal"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8717","authenticated-orcid":false,"given":"Diogo","family":"Mendes","sequence":"first","affiliation":[]},{"given":"Carlos","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Batel-Marques","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"issue":"26","key":"875_CR1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","volume":"318","author":"A Laupacis","year":"1988","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728\u201333.","journal-title":"N Engl J Med"},{"key":"875_CR2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"D Cook","year":"1995","unstructured":"Cook D, Sackett D. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452\u20134.","journal-title":"BMJ"},{"issue":"6","key":"875_CR3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1503\/cmaj.080484","volume":"179","author":"FA McAlister","year":"2008","unstructured":"McAlister FA. The \u201cnumber needed to treat\u201d turns 20\u2014and continues to be used and misused. CMAJ. 2008;179(6):549\u201353.","journal-title":"CMAJ"},{"key":"875_CR4","volume-title":"Evidence-based medicine: how to practice and teach it","author":"SE Straus","year":"2011","unstructured":"Straus SE, Glasziou P, Richardson WS, Haynes RB. Evidence-based medicine: how to practice and teach it. London: Churchill Livingstone; 2011."},{"issue":"5","key":"875_CR5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L Citrome","year":"2013","unstructured":"Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407\u201311.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"875_CR6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/pds.3636","volume":"23","author":"S Mt-Isa","year":"2014","unstructured":"Mt-Isa S, Hallgreen CE, Wang N, et al. IMI-PROTECT benefit-risk participants. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. 2014;23(7):667\u201378.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"875_CR7","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pds.3874","volume":"24","author":"D Mendes","year":"2015","unstructured":"Mendes D, Alves C, Batel-Marques F. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2015;24(12):1259\u201370.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"875_CR8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14740338.2016.1217989","volume":"15","author":"D Mendes","year":"2016","unstructured":"Mendes D, Alves C, Batel MF. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opin Drug Saf. 2016;15(10):1301\u201312.","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"875_CR9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","volume":"134","author":"DG Altman","year":"2001","unstructured":"Altman DG, Schulz KF, Moher D, CONSORT GROUP (Consolidated Standards of Reporting Trials), et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663\u201394.","journal-title":"Ann Intern Med."},{"key":"875_CR10","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"340","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.","journal-title":"BMJ"},{"key":"875_CR11","unstructured":"BMJ. For Authors, Resources for Authors, Article Types, Research. bmj.com. http:\/\/www.bmj.com\/about-bmj\/resources-authors\/article-types\/research . Accessed 13 Oct 2016."},{"key":"875_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2288-9-21","volume":"9","author":"M Hildebrandt","year":"2009","unstructured":"Hildebrandt M, Verv\u00f6lgyi E, Bender R. Calculation of NNTs in RCTs with time-to-event outcomes: a literature review. BMC Med Res Methodol. 2009;9:21.","journal-title":"BMC Med Res Methodol"},{"issue":"21","key":"875_CR13","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1001\/jama.287.21.2813","volume":"287","author":"J Nuovo","year":"2002","unstructured":"Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA. 2002;287(21):2813\u20134.","journal-title":"JAMA"},{"key":"875_CR14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jclinepi.2015.11.002","volume":"72","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, et al. Systematic reviews experience major limitations in reporting absolute effects. J Clin Epidemiol. 2016;72:16\u201326.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"875_CR15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0447.2009.01449.x","volume":"121","author":"L Citrome","year":"2010","unstructured":"Citrome L. Relative vs. absolute measures of benefit and risk: what\u2019s the difference? Acta Psychiatr Scand. 2010;121(2):94\u2013102.","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"875_CR16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1212\/WNL.0b013e3181b9c8f7","volume":"73","author":"EC Klawiter","year":"2009","unstructured":"Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? Neurology. 2009;73(12):984\u201390.","journal-title":"Neurology"},{"issue":"10","key":"875_CR17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40263-016-0377-9","volume":"30","author":"D Mendes","year":"2016","unstructured":"Mendes D, Alves C, Batel-Marques F. Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis. CNS Drugs. 2016;30(10):909\u201329.","journal-title":"CNS Drugs"},{"issue":"9","key":"875_CR18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.7326\/0003-4819-126-9-199705010-00007","volume":"126","author":"HJ McQuay","year":"1997","unstructured":"McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712\u201320.","journal-title":"Ann Intern Med"},{"key":"875_CR19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","volume":"31","author":"TA Furukawa","year":"2002","unstructured":"Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the \u2018number needed to treat\u2019? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 2002;31:72\u20136.","journal-title":"Int J Epidemiol"},{"key":"875_CR20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-2-2","volume":"2","author":"RA Moore","year":"2002","unstructured":"Moore RA, Gavaghan DJ, Edwards JE, et al. Pooling data for number needed to treat: no problems for apples. BMC Med Res Methodol. 2002;2:2.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"875_CR21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2202\/1557-4679.1285","volume":"7","author":"PC Austin","year":"2011","unstructured":"Austin PC, Laupacis A. A tutorial on methods to estimating clinically and policy-meaningful measures of treatment effects in prospective observational studies: a review. Int J Biostat. 2011;7(1):6.","journal-title":"Int. J. Biostat."},{"issue":"5","key":"875_CR22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0895-4356(01)00510-8","volume":"55","author":"R Bender","year":"2002","unstructured":"Bender R, Blettner M. Calculating the \u201cnumber needed to be exposed\u201d with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol. 2002;55(5):525\u201330.","journal-title":"J Clin Epidemiol"},{"issue":"30","key":"875_CR23","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1002\/sim.3061","volume":"26","author":"R Bender","year":"2007","unstructured":"Bender R, Kuss O, Hildebrandt M, Gehrmann U. Estimating adjusted NNT measures in logistic regression analysis. Stat Med. 2007;26(30):5586\u201395.","journal-title":"Stat Med"},{"issue":"7168","key":"875_CR24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"DG Altman","year":"1998","unstructured":"Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317(7168):1309\u201312.","journal-title":"BMJ"},{"key":"875_CR25","first-page":"3752","volume-title":"Encyclopedia of biostatistics","author":"R Bender","year":"2005","unstructured":"Bender R. Number needed to treat (NNT). In: Armitage P, Colton T, editors. Encyclopedia of biostatistics. Chichester: Wiley; 2005. p. 3752\u201361."},{"issue":"7223","key":"875_CR26","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1136\/bmj.319.7223.1492","volume":"319","author":"DG Altman","year":"1999","unstructured":"Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492\u20135.","journal-title":"BMJ"},{"issue":"7233","key":"875_CR27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/bmj.320.7233.503","volume":"320","author":"LM Bjerre","year":"2000","unstructured":"Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case\u2013control studies: \u201cthe number of patients needed to be treated for one additional patient to be harmed\u201d. BMJ. 2000;320(7233):503\u20136.","journal-title":"BMJ"},{"issue":"9","key":"875_CR28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jclinepi.2013.01.011","volume":"66","author":"R Bender","year":"2013","unstructured":"Bender R, Kromp M, Kiefer C, Sturtz S. Absolute risks rather than incidence rates should be used to estimate the number needed to treat from time-to-event data. J Clin Epidemiol. 2013;66(9):1038\u201344.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"875_CR29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2011.04.009","volume":"65","author":"D Suissa","year":"2012","unstructured":"Suissa D, Brassard P, Smiechowski B, Suissa S. Number needed to treat is incorrect without proper time-related considerations. J Clin Epidemiol. 2012;65(1):42\u20136.","journal-title":"J Clin Epidemiol"},{"key":"875_CR30","first-page":"6(3)","volume":"30","author":"S Suissa","year":"2015","unstructured":"Suissa S. The number needed to treat: 25\u00a0years of trials and tribulations in clinical research. Rambam Maimonides Med J. 2015;30:6(3).","journal-title":"Rambam Maimonides Med J"},{"key":"875_CR31","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0","author":"JJ Deeks","year":"2011","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. Oxford: The Cochrane Collaboration; 2011."},{"issue":"5","key":"875_CR32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/ije\/dys124","volume":"41","author":"BR Costa da","year":"2012","unstructured":"da Costa BR, Rutjes AW, Johnston BC, et al. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. Int J Epidemiol. 2012;41(5):1445\u201359.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"875_CR33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMc0903274","volume":"361","author":"S Suissa","year":"2009","unstructured":"Suissa S. Calculation of number needed to treat. N Engl J Med. 2009;361(4):424\u20135.","journal-title":"N Engl J Med"},{"issue":"8","key":"875_CR34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jclinepi.2009.08.006","volume":"63","author":"A Stang","year":"2010","unstructured":"Stang A, Poole C, Bender R. Common problems related to the use of number needed to treat. J Clin Epidemiol. 2010;63(8):820\u20135.","journal-title":"J Clin Epidemiol"},{"key":"875_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-2-1","volume":"2","author":"CJ Cates","year":"2002","unstructured":"Cates CJ. Simpson\u2019s paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol. 2002;2:1.","journal-title":"BMC Med Res Methodol"},{"key":"875_CR36","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","volume":"318","author":"L Smeeth","year":"1999","unstructured":"Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses \u2014 sometimes informative, usually misleading. BMJ. 1999;318:1548\u201351.","journal-title":"BMJ"},{"key":"875_CR37","unstructured":"Thomson-Reuters. Journal citation reports. http:\/\/thomsonreuters.com\/en\/products-services\/scholarly-scientific-research\/research-management-and-evaluation\/journal-citation-reports.html . Accessed 24 Aug 2016."},{"issue":"1","key":"875_CR38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pds.2260","volume":"21","author":"C Alves","year":"2012","unstructured":"Alves C, Batel-Marques F, Macedo AF. Data sources on drug safety evaluation: a review of recent published meta-analyses. Pharmacoepidemiol Drug Saf. 2012;21(1):21\u201333.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"875_CR39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"issue":"17","key":"875_CR40","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6","volume":"17","author":"CH Schmid","year":"1998","unstructured":"Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17(17):1923\u201342.","journal-title":"Stat Med"},{"issue":"13","key":"875_CR41","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/1097-0258(20000715)19:13<1707::AID-SIM491>3.0.CO;2-P","volume":"19","author":"EA Engels","year":"2000","unstructured":"Engels EA, Schmid CH, Terrin N, et al. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Stat Med. 2000;19(13):1707\u201328.","journal-title":"Stat Med"},{"issue":"1","key":"875_CR42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2009.03.012","volume":"63","author":"PC Austin","year":"2010","unstructured":"Austin PC. Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes. J Clin Epidemiol. 2010;63(1):46\u201355.","journal-title":"J Clin Epidemiol"},{"issue":"7\u20138","key":"875_CR43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/sim.3793","volume":"29","author":"RP Laubender","year":"2010","unstructured":"Laubender RP, Bender R. Estimating adjusted risk difference (RD) and number needed to treat (NNT) measures in the Cox regression model. Stat Med. 2010;29(7\u20138):851\u20139.","journal-title":"Stat Med"},{"issue":"5","key":"875_CR44","first-page":"810","volume":"33","author":"RP Laubender","year":"2014","unstructured":"Laubender RP, Bender R. A note on calculating asymptotic confidence intervals for the adjusted risk difference and number needed to treat in the Cox regression model. Stat Med. 2014;33(5):798\u2013810. Correction: Stat Med. 2014;33(5):810\u20131.","journal-title":"Correction: Stat Med"},{"issue":"8","key":"875_CR45","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/jech.56.8.606","volume":"56","author":"RF Heller","year":"2002","unstructured":"Heller RF, Dobson AJ, Attia J, Page J. Impact numbers: measures of risk factor impact on the whole population from case\u2013control and cohort studies. J Epidemiol Community Health. 2002;56(8):606\u201310.","journal-title":"J Epidemiol Community Health"},{"issue":"8","key":"875_CR46","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jech.56.8.600","volume":"56","author":"J Attia","year":"2002","unstructured":"Attia J, Page J, Heller RF, Dobson AJ. Impact numbers in health policy decisions. J Epidemiol Community Health. 2002;56(8):600\u20135.","journal-title":"J Epidemiol Community Health"},{"key":"875_CR47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2458-3-7","volume":"3","author":"RF Heller","year":"2003","unstructured":"Heller RF, Edwards R, McElduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health. 2003;3:7.","journal-title":"BMC Public Health"},{"issue":"7424","key":"875_CR48","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/bmj.327.7424.1162","volume":"327","author":"RF Heller","year":"2003","unstructured":"Heller RF, Buchan I, Edwards R, et al. Communicating risks at the population level: application of population impact numbers. BMJ. 2003;327(7424):1162\u20135.","journal-title":"BMJ"},{"issue":"3","key":"875_CR49","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/1467-985X.00175","volume":"163","author":"JL Hutton","year":"2000","unstructured":"Hutton JL. Number needed to treat: properties and problems. J R Stat Soc A Stat Soc. 2000;163(3):403\u201319.","journal-title":"J. R. Stat. Soc. A. Stat. Soc."},{"key":"875_CR50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2288-2-3","volume":"2","author":"DG Altman","year":"2002","unstructured":"Altman DG, Deeks JJ. Meta-analysis, Simpson\u2019s paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"875_CR51","doi-asserted-by":"crossref","first-page":"A11","DOI":"10.7326\/ACPJC-2003-138-2-A11","volume":"138","author":"A Marx","year":"2003","unstructured":"Marx A, Bucher HC. Numbers needed to treat derived from meta-analysis: a word of caution. ACP J Club. 2003;138(2):A11\u20132.","journal-title":"ACP J Club"},{"issue":"8","key":"875_CR52","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0025-6196(11)60763-5","volume":"83","author":"J Shepherd","year":"2008","unstructured":"Shepherd J, Kastelein JP, Bittner VA, et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83(8):870\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"9243","key":"875_CR53","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(00)03215-3","volume":"356","author":"J Lubsen","year":"2000","unstructured":"Lubsen J, Hoes A, Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet. 2000;356(9243):1757\u20139.","journal-title":"Lancet"},{"issue":"3","key":"875_CR54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jclinepi.2005.07.006","volume":"59","author":"TJ Mayne","year":"2006","unstructured":"Mayne TJ, Whalen E, Vu A. Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions. J Clin Epidemiol. 2006;59(3):217\u201323.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"875_CR55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jclinepi.2013.08.010","volume":"67","author":"N Girerd","year":"2014","unstructured":"Girerd N, Rabilloud M, Duarte K, Roy P. Number needed to treat from absolute risk and incidence rate: how to make apples and oranges comparable? J Clin Epidemiol. 2014;67(2):236\u20138.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"875_CR56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jclinepi.2013.08.009","volume":"67","author":"R Bender","year":"2014","unstructured":"Bender R, Kromp M, Kiefer C, Sturtz S. Estimation of numbers needed to treat should be based on absolute risks. J Clin Epidemiol. 2014;67(2):238\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"875_CR57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/thoraxjnl-2012-202709","volume":"68","author":"S Suissa","year":"2013","unstructured":"Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax. 2013;68(6):540\u20133.","journal-title":"Thorax"},{"issue":"4","key":"875_CR58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","volume":"304","author":"DJ Graham","year":"2010","unstructured":"Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411\u20138.","journal-title":"JAMA"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-017-0875-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T21:32:44Z","timestamp":1692826364000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-017-0875-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1186\/s12916-017-0875-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]},"article-number":"112"}}